PharmaPendium®
2018.24 Release

The content release includes the following updates

Legend
○ Content Updates
● Data Updates

1. 8 New Drugs in PharmaPendium
   - Baloxavir Marboxil
   - Coagulation Factor XA (Recombinant), Inactivated
   - Emapalumab
   - Estradiol; Progesterone
   - Glasdegib
   - Larotrectinib
   - Lorlatinib
   - Revefenacin

2. FDA Approval Documents
   - 253 new FDA Approval Documents
   - 5,103 new pages of FDA Approval Documents

3. FDA Advisory Committee Documents
   - 128 new FDA Advisory Committee Documents
   - 4,691 new pages of FDA Advisory Committee Documents

4. The new totals for PharmaPendium are:
   - 2,541,339 pages of FDA Approval documents
     (Including FDA Classic Collection)
   - 116,228 documents of FDA Approval documents
     (Including FDA Classic Collection)
   - 4,574 drugs with data in PharmaPendium
   - 1,832,998 extracted safety data lines
   - 1,712,465 extracted PK data lines
   - 338,690 extracted ME data lines
   - 2,919,617 extracted Efficacy data lines
   - 128,749 extracted Activity data lines
   - 12,285,596 FAERS (post-marketing) reports
   - 12,879 documents / 235,642 pages of EMA Approval documents
   - 18,304 documents / 719,718 pages of FDA Advisory Committees Meetings documents
   - 10,906 documents / 308,149 pages of FDA Classic Collection
   - 2,769 documents / 32,290 pages of DESI documents

Copyright © 2019 Elsevier Life Sciences IP Limited. All rights reserved. PharmaPendium is a trade mark of Elsevier Life Sciences IP Limited. RELX Group and the RE symbol are trade marks of RELX Group plc, used under license. January 2019